Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.59 |
| ▸ | AR | P10275 | 11/20 | 0.50 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.47 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.47 |
| ▸ | CNR2 | P34972 | 2/20 | 0.46 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.45 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL945128 | 1.00 | TRPA1 (0.59) | TRPA1ARPRKCQPRKCDCNR2 | |
| SCHEMBL945129 | 1.00 | TRPA1 (0.59) | TRPA1ARPRKCQPRKCDCNR2 | |
| SCHEMBL15353735 | 0.86 | TRPA1 (0.45) | TRPA1ARPRKCQPRKCDCNR2 | |
| SCHEMBL12917310 | 0.86 | TRPA1 (0.45) | TRPA1ARPRKCQPRKCDCNR2 | |
| SCHEMBL20274188 | 0.86 | TRPA1 (0.53) | TRPA1ARCNR2TAS2R14SLC22A12 | |
| SCHEMBL29666012 | 0.86 | TRPA1 (0.53) | TRPA1ARCNR2TAS2R14SLC22A12 | |
| SCHEMBL20274107 | 0.86 | TRPA1 (0.61) | TRPA1ARCNR2 | |
| SCHEMBL28222848 | 0.85 | TRPA1 (0.54) | TRPA1ARCNR2TAS2R14SLC22A12 | |
| SCHEMBL16321793 | 0.85 | TRPA1 (0.57) | TRPA1ARCNR2TAS2R14SLC22A12 | |
| SCHEMBL381677 | 0.84 | TRPA1 (0.53) | TRPA1ARCNR2TAS2R14SLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569495-B2 | Anthelmintic agents and their use | INTERVET INTERNATIONAL B.V. (NL) | 2013-10-29 | — | — | US | disclosed |
| US-20120094981-A1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INTERNATIONAL B.V. (NL) | 2012-04-19 | — | — | US | disclosed |
| US-20110021506-A1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INTERNATIONAL B.V. (NL) | 2011-01-27 | — | — | US | disclosed |
| US-20110021506-A1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INTERNATIONAL B.V. (NL) | 2011-01-27 | — | — | US | disclosed |
| WO-2009077527-A1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INTERNATIONAL B.V. (NL) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021506-A1 | ANTHELMINTIC AGENTS AND THEIR USE | ACHE, ABCB11, MPO | TRPA1 293/4885AR 4080/4885PRKCQ 2502/4885 |
| US-20120094981-A1 | ANTHELMINTIC AGENTS AND THEIR USE | ABCB11, ACHE, CMA1 | TRPA1 530/4885AR 4346/4885PRKCQ 2694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.